Jun 05, 2026
Summary The EGFR-mutant NSCLC treatment market was valued at USD 6.6 billion in 2025 and is projected to grow at a 7.3% CAGR over the next decade, driven largely by the emergence of targeted biologics and ADCs. The recent approval of Dato-DXd marks a major milestone and is expected to accelerate the adoption...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper